News B.R.A.I.N. Biotechnology Research and Information Network AG OTC Markets

Stocks

BRNB.F

DE0005203947

Environmental Services & Equipment

All News

Mentions Relevance

08-27	BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
08-27	BRAIN Biotech reports its 9M results and continues to target a break-even adjusted Group-EBITDA	EQ
07-29	BRAIN Biotech AG Announces CEO Changes	CI
07-29	BRAIN Biotech AG Announces Change of Chairman of Executive Board	CI
07-29	Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG	EQ
07-29	BRAIN Biotech : Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG	PU
07-29	BRAIN Biotech AG Appoints Dr. Sven K. Weber as New Chairman of the Executive Board, Effective October 1, 2026	EQ
07-13	Brain Biotech Ag Signs New Revolving Credit Facility with Mp Beteiligungs-Gmbh	CI
07-13	Brain Biotech Secures EUR9 Million Revolving Credit Facility	MT
07-13	BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH	EQ
06-08	BRAIN Biotech AG, H1 2026 Earnings Call, May 28, 2026
05-28	BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
05-28	BRAIN Biotech : Management Statement 6M 2025/26 (BRAIN 6M 2025 26 Managementstatement)	PU
05-28	BRAIN Biotech : Half-year report as of 31 March 2026 (6M)	PU
05-28	BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance	EQ
03-23	BRAIN Biotech Secures European Patent for Genome-editing Technology	MT
03-23	BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology	EQ
03-11	Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG	EQ
03-09	BRAIN Biotech : Sustainability Report VSME for FJ 2023/24	PU
02-25	BRAIN Biotech : Management Statement 3M 2025/26 (BRAIN Managementstatement 3M 2025 26 )	PU
02-25	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase® Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	PU
02-25	BRAIN Biotech : Quarterly Statement as of 31 December 2025 (3M)	PU
02-25	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	EQ
02-24	BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-20	BRAIN Biotech AG, 2025 Earnings Call, Jan 14, 2026